SPIA
ALXN

Steward Partners Investment Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Steward Partners Investment Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,641
Closed -$301K – 3477
2021
Q2 		$301K Buy
1,641
+149
+10% +$25.6K 0.01% 1185
2021
Q1 		$228K Sell
1,492
-17
-1% -$2.63K ﹤0.01% 1234
2020
Q4 		$236K Sell
1,509
-783
-34% -$101K 0.01% 1003
2020
Q3 		$262K Buy
2,292
+481
+27% +$51.9K 0.01% 851
2020
Q2 		$203K Buy
1,811
+152
+9% +$16.1K 0.01% 880
2020
Q1 		$148K Buy
1,659
+738
+80% +$72.4K 0.01% 877
2019
Q4 		$99K Buy
921
+757
+462% +$81K ﹤0.01% 1142
2019
Q3 		$16K Sell
164
-52
-24% -$5.86K ﹤0.01% 1820
2019
Q2 		$28K Buy
+216
New +$27.8K ﹤0.01% 1581
2018
Q4 		– Sell
-312
Closed -$43K – 2420
2018
Q3 		$43K Sell
312
-197
-39% -$24.7K ﹤0.01% 1269
2018
Q2 		$63K Sell
509
-211
-29% -$24.7K ﹤0.01% 1010
2018
Q1 		$80K Sell
720
-720
-50% -$86.1K 0.01% 840
2017
Q4 		$172K Sell
1,440
-519
-26% -$63.2K 0.01% 547
2017
Q3 		$274K Buy
1,959
+130
+7% +$17.7K 0.03% 384
2017
Q2 		$222K Buy
1,829
+355
+24% +$41.3K 0.02% 386
2017
Q1 		$178K Buy
1,474
+1,217
+474% +$157K 0.03% 339
2016
Q4 		$31K Buy
+257
New +$31.4K 0.01% 397

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Steward Partners Investment Advisory's ALXN Position: Q3 2021 in Review

Steward Partners Investment Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,641 shares — an estimated $301K sold.

Steward Partners Investment Advisory first reported a position in ALXN in Q4 2016 and held it in 17 quarters. The position peaked at $301K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Steward Partners Investment Advisory reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 1,641 Alexion Pharmaceuticals shares in Q3 2021, an estimated $301K.
  • Steward Partners Investment Advisory first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 17 quarters.
  • Steward Partners Investment Advisory's Alexion Pharmaceuticals position peaked at $301K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.